What do systematic reviews say?

Fondaparinux vs placebo

Fondaparinux probably leads to lower total VTE compared with placebo (moderate certainty).

• Pentasaccharides for the prevention of venous thromboembolism 2016 · Cochrane Headline outcomes only
  RR 0.24 [0.15, 0.38]
  8 studies · 5717 participants
  Moderate

Fondaparinux vs variable dose warfarin

• Pentasaccharides for the prevention of venous thromboembolism 2016 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 236 participants
  Very low

Fondaparinux vs 1 mg warfarin

It is very uncertain whether fondaparinux changes total VTE compared with 1 mg warfarin (very low certainty).

• Pentasaccharides for the prevention of venous thromboembolism 2016 · Cochrane Headline outcomes only
  RR 0.2 [0.01, 4.12]
  1 study · 236 participants
  Very low

Fondaparinux vs edoxaban

• Pentasaccharides for the prevention of venous thromboembolism 2016 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 38 participants
  Very low

Fondaparinux vs mechanical thromboprophylaxis

Fondaparinux showed no clear difference in total VTE compared with mechanical thromboprophylaxis (low certainty).

• Pentasaccharides for the prevention of venous thromboembolism 2016 · Cochrane Headline outcomes only
  RR 0.61 [0.22, 1.67]
  1 study · 99 participants
  Low

Fondaparinux vs low molecular weight heparin

Fondaparinux probably leads to lower total VTE compared with LMWH (moderate certainty).

• Pentasaccharides for the prevention of venous thromboembolism 2016 · Cochrane Headline outcomes only
  RR 0.55 [0.42, 0.73]
  11 studies · 9339 participants
  Moderate